The funding was led by China Reform Holdings and joined by ChinaEquity Group and several unnamed investors.
November 24, 2017 -- 3D Medicines, a Beijing biopharma, closed a $101 million fundraising. 3DMed says its name stands for its three separate oncology technologies: diagnostics, data, and drug development. The company offers next-gen sequencing for early-stage cancer detection, precision medicine diagnosis and innovative drug development. The funding was led by China Reform Holdings (via China State-Owned Assets Venture Investment Fund) and joined by ChinaEquity Group and several unnamed investors.
